OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc.

OKUR - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$140.8M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
OnKure Therapeutics, Inc.OnKure Therapeutics, Inc.-0.9--21%--
$14.00

Target Price by Analysts

396.5% upsideOnKure Therapeutics Target Price DetailsTarget Price
$4.33

Current Fair Value

53.5% upside

Undervalued by 53.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$140.80 Million
Enterprise Value$-9,855,614.00
Earnings per Share$-4.4
Beta0.3
Outstanding Shares49,928,151

Return

Return on Equity-21.04%ROE
Return on Assets-19.87%
Return on Invested Capital-41.69%

Valuation & Multiples

P/E Ratio-0.95P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio0.94Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.67
Enterprise Value to Net Income0
Total Debt to Enterprise-0.02
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS Estimate
-$0.41
Consensus analyst estimate
Revenue Estimate
$166,667
Consensus analyst estimate

Next Earnings Call

Expected Date
March 11, 2027
EPS Estimate
-$0.35
Consensus analyst estimate
Revenue Estimate
$250,000
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %21.04%▼ 49.00%
Total Invested$28.60M▼ 82.05%
Investors Holding43▼ 33.00%

About Reneo Pharmaceuticals Inc

18 employees
CEO: Nicholas A. Saccomano

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produc...

OnKure Therapeutics Insider Information FAQ

Stockcircle shows 4 open-market insider sales for OnKure Therapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.